Uniqure NV

Stock Chart, Company Information, and Scan Results

$50.10(as of Sep 25, 10:29 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Uniqure NV Company Information, Fundamentals, and Technical Indicators

Stock Price$50.10

Ticker SymbolQURE

ExchangeNasdaq

SectorHealthcare

IndustryBiotechnology

Employees209

CountyUSA

Market Cap$749.5M

EBIDTA-146.4M

10-Day Moving Average18.05

P/E Ratio-13.08

20-Day Moving Average17.57

Forward P/E Ratio27.93

50-Day Moving Average15.86

Earnings per Share-3.90

200-Day Moving Average14.41

Profit Margin-716.82%

RSI91.01

Shares Outstanding54.9M

ATR3.54

52-Week High51.21

Volume69,963,623

52-Week Low4.45

Most Recent Support Level13.65

Book Value-4.0M

Most Recent Resistance Level15.40

P/B Ratio-650.36

Upper Keltner25.54

P/S Ratio181.58

Lower Keltner9.59

Debt-to-Equity Ratio25.54

Next Earnings Date10/29/2025

Cash Surplus212.8M

Next Ex-Dividend DateUnknown

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Uniqure NV In Our Stock Scanner

As of Sep 25, 2025

example chart graphic

Scan Name: Cash SurplusScan Type: Stock Fundamentals

As of ---

example chart graphic

Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals

As of ---

example chart graphic

Scan Name: 52-Week HighScan Type: Stock Fundamentals

As of ---

example chart graphic

Scan Name: Most Volatile StocksScan Type: Stock Indicator Scans

As of ---

example chart graphic

Scan Name: Momentum StocksScan Type: Stock Indicator Scans

As of ---

example chart graphic

Scan Name: Unusual VolumeScan Type: Stock Indicator Scans

As of ---

example chart graphic

Scan Name: Heikin Ashi BreakoutScan Type: Candlestick Pattern Scans

As of ---

example chart graphic

Scan Name: Low PB RatioScan Type: Stock Fundamentals

As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.